Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun;25(6):637-45.
doi: 10.1002/pds.3951. Epub 2015 Dec 29.

Trends in prescribing of sedative-hypnotic medications in the USA: 1993-2010

Christopher N Kaufmann  1   2   3 , Adam P Spira  1 , G Caleb Alexander  2   4 , Lainie Rutkow  5 , Ramin Mojtabai  1   2
Affiliations

Trends in prescribing of sedative-hypnotic medications in the USA: 1993-2010

Christopher N Kaufmann et al. Pharmacoepidemiol Drug Saf. 2016 Jun.

Abstract

Purpose: Non-benzodiazepine receptor agonists (nBZRAs) were developed as an alternative to benzodiazepines (BZDs) to treat insomnia. Little is known about how the introduction of nBZRAs influenced trends in BZD prescribing. We examined BZD and nBZRA prescribing trends from 1993 to 2010.

Methods: We used the National Ambulatory Medical Care Survey to examine 516,118 patient visits between 1993 and 2010. We categorized visits as BZD, nBZRA, or BZD + nBZRA visits based on medications prescribed in each visit and applied linear probability regression models to assess trends in visits.

Results: Increases were observed in proportions of visits that were BZD (2.6% in 1993 to 4.4% in 2010, p < 0.001) and nBZRA (0% to 1.4%, p < 0.001). Increases in BZD visits were primarily after 2002, with prescribing in the preceding years remaining relatively stable. We also found increases in BZD + nBZRA visits (0% to 0.4%, p < 0.001). Among patients with sleep disorders, there was an increase in nBZRA visits (2.3% to 13.7%, p < 0.001), and decline in BZD visits (23.5% to 10.8%, p = 0.015). Just under a third (30.8%) of any sedative-hypnotic visits were for adults aged 65+ years, among whom increases in BZD, nBZRA, and BZD + nBZRA visits were observed across the study period.

Conclusions: There were increases in prescribing of nBZRAs between 1993 and 2010. Increases in prescribing of BZDs were also observed, especially after 2002. The introduction of nBZRAs likely resulted in declines in BZD prescribing among those with a sleep disorder, but not other groups. Delivery of behavioral treatments should be encouraged to avert adverse outcomes associated with sedative-hypnotic use. Copyright © 2015 John Wiley & Sons, Ltd.

Keywords: anxiety; pharmacoepidemiology; prescribing trends; sedative-hypnotics; sleep.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Dr. Mojtabai has received research funding from Bristol Myers Squibb and consultant fees from Lundbeck Pharmaceuticals. All other authors have no disclosures to report.

Figures

Fig. 1
Fig. 1
Fig. 2
Fig. 2
See this image and copyright information in PMC

References

    1. Bertisch SM, Herzig SJ, Winkelman JW, Buettner C. National Use of Prescription Medications for Insomnia: NHANES 1999–2010. Sleep. 2014;37(2):343–349. doi: 10.5665/sleep.3410. - DOI - PMC - PubMed
    1. Costa e Silva JA. Sleep disorders in psychiatry. Metab Clin Exp. 2006;55(10 Suppl 2):S40–S44. - PubMed
    1. Allgulander C. History and current status of sedative-hypnotic drug use and abuse. Acta Psychiatr Scand. 1986;73(5):465–478. - PubMed
    1. Food and Drug Administration. Ambien Approval Letter. http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019908_S000_AP&A.... Accessed June 18, 2014.
    1. Food and Drug Administration. Sonata Approval Letter. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/1999/20859ltr.pdf. Accessed June 17, 2014.

Publication types